{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:31:39Z","timestamp":1784903499652,"version":"3.55.0"},"reference-count":13,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T00:00:00Z","timestamp":1487635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["HHSF223200910006I"],"award-info":[{"award-number":["HHSF223200910006I"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2017,5]]},"abstract":"Abstract<\/jats:title>Purpose<\/jats:title>To examine ondansetron use in pregnancy in the context of other antiemetic use among a large insured United States population of women delivering live births.<\/jats:p><\/jats:sec>Methods<\/jats:title>We assessed ondansetron and other antiemetic use among pregnant women delivering live births between 2001 and 2015 in 15 data partners contributing data to the Mini\u2010Sentinel Distributed Database. We identified live birth pregnancies using a validated algorithm, and all forms of ondansetron and other available antiemetics were identified using National Drug Codes or procedure codes. We assessed the prevalence of antiemetic use by trimester, calendar year, and formulation.<\/jats:p><\/jats:sec>Results<\/jats:title>In over 2.3 million pregnancies, the prevalence of ondansetron, promethazine, metoclopramide, or doxylamine\/pyridoxine use anytime in pregnancy was 15.2, 10.3, 4.0, and 0.4%, respectively. Ondansetron use increased from <1% of pregnancies in 2001 to 22.2% in 2014, with much of the increase attributable to oral ondansetron beginning in 2006. Promethazine and metoclopramide use increased modestly between 2001 (13.8%, 3.2%) and 2006 (16.0%, 6.0%) but decreased annually through 2014 (8.0%, 3.2%). Doxylamine\/pyridoxine, approved for management of nausea and vomiting in pregnancy in 2013, was used in 1.8% of pregnancies in 2014. For all antiemetics, use was highest in the first trimester.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>We observed a marked increase in ondansetron use by study year, prescribed to nearly one\u2010quarter of insured pregnant women in 2014, occurring in conjunction with decreased use of promethazine and metoclopramide. Given the widespread use of ondansetron in pregnancy, data establishing product efficacy and methodologically rigorous evaluation of post\u2010marketing safety are needed. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4185","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T16:03:35Z","timestamp":1487693015000},"page":"592-596","source":"Crossref","is-referenced-by-count":56,"title":["Antiemetic use among pregnant women in the United States: the escalating use of ondansetron"],"prefix":"10.1002","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8996-6455","authenticated-orcid":false,"given":"Lockwood G.","family":"Taylor","sequence":"first","affiliation":[{"name":"Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Bird","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Sahin","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa S.","family":"Tassinari","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patty","family":"Greene","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marsha E.","family":"Reichman","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Andrade","sequence":"additional","affiliation":[{"name":"Meyers Primary Care Institute (Fallon Community Health Plan, Reliant Medical Group, and University of Massachusetts Medical School) Worcester MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Haffenreffer","sequence":"additional","affiliation":[{"name":"Department of Population Medicine Harvard Medical School and Harvard Pilgrim Health Care Institute Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sengwee","family":"Toh","sequence":"additional","affiliation":[{"name":"Department of Population Medicine Harvard Medical School and Harvard Pilgrim Health Care Institute Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,2,21]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"MatthewsA HaasDM O'MathunaDP DowswellT DoyleM.Interventions for nausea and vomiting in early pregnancy. Cochrane Database Syst Rev 2014;3:CD007575."},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(02)02024-0"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2011.03023.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.22865"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2014.10.017"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1014427"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2336"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3407"},{"key":"e_1_2_8_10_1","unstructured":"RosatiK EB &McGrawD.HIPAA and common rule compliance in the Mini\u2010Sentinel pilot white paper 2014."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-005-0055-1"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2004.00236.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1211035"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000001048"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4185","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T11:17:16Z","timestamp":1696504636000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,21]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1002\/pds.4185"],"URL":"https:\/\/doi.org\/10.1002\/pds.4185","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,21]]}}}